RT Journal Article
SR Electronic
T1 Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.21.20198309
DO 10.1101/2020.09.21.20198309
A1 Anwar M Hashem
A1 Abdullah Algaissi
A1 Sarah A Almahboub
A1 Mohamed A Alfaleh
A1 Turki S Abujamel
A1 Sawsan S Alamri
A1 Khalid A Alluhaybi
A1 Haya I Hobani
A1 Rahaf H AlHarbi
A1 Reem M Alsulaiman
A1 M-Zaki ElAssouli
A1 Sharif Hala
A1 Naif K Alharbi
A1 Rowa Y Alhabbab
A1 Ahdab A AlSaieedi
A1 Wesam H Abdulaal
A1 Abdullah Bukhari
A1 Afrah A AL-Somali
A1 Fadwa S Alofi
A1 Asim A Khogeer
A1 Arnab Pain
A1 Almohanad A Alkayyal
A1 Naif AM Almontashiri
A1 Ahmad Bakur Mahmoud
A1 Xuguang Li
YR 2020
UL http://medrxiv.org/content/early/2020/09/23/2020.09.21.20198309.abstract
AB The Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Immunological surrogate markers, in particular antigen-specific responses, are of unquestionable value for clinical management of patients with COVID-19. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized patients with RT-PCR confirmed COVID-19 infection. Our data show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Notably, anti-S and -N IgG, peaked 20-40 day after disease onset, and were still detectable for at least up to 70 days, with nAbs observed during the same time period. Moreover, nAbs titers were strongly correlated with IgG antibodies. Significantly higher levels of nAbs as well as anti-S1 and N IgG and IgM antibodies were found in patients with more severe clinical presentations, patients requiring admission to intensive care units (ICU) or those with fatal outcomes. Interestingly, lower levels of antibodies, particularly anti-N IgG and IgM in the first 15 days after symptoms onset, were found in survivors and those with mild clinical presentations. Collectively, these findings provide new insights into the characteristics and kinetics of antibody responses in COVID-19 patients with different disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number (436).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Approval Unit at King Abdulaziz University IRB committee, Ministry of Health, Saudi ArabiaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe confirm that all data related to the study are included in the manuscript